Sun-Novo(SH:688621) Shang Hai Zheng Quan Bao·2025-10-28 23:18Core Viewpoint - The board of directors of Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. has approved the grant of reserved restricted stocks under the 2025 Restricted Stock Incentive Plan, with a total of 544,355 shares to be granted at a price of 22.62 yuan per share to 13 eligible incentive objects [2][9][28]. Group 1: Board Meeting Details - The second meeting of the second board of directors was held on October 28, 2025, with all 9 directors present, complying with relevant laws and regulations [1][3]. - The meeting unanimously approved the resolution regarding the grant of reserved restricted stocks [3]. Group 2: Restricted Stock Grant Details - The reserved stock grant date is set for October 28, 2025, with a total of 544,355 shares, accounting for approximately 0.49% of the company's total issued shares of 11.2 million [6][7]. - The stock incentive method is classified as restricted stock (Type II restricted stock) [8]. Group 3: Grant Conditions and Procedures - The board confirmed that the conditions for granting the reserved restricted stocks have been met, and the grant does not require shareholder approval [9][15]. - The grant price was adjusted from 22.78 yuan to 22.62 yuan per share due to the company's dividend distribution [14][12]. Group 4: Compliance and Eligibility - The board and the remuneration and assessment committee verified that both the company and the incentive objects meet all necessary legal and regulatory conditions for the stock grant [16][18]. - The incentive objects are all formal employees of the company and do not include independent directors or major shareholders [25][26]. Group 5: Financial Impact and Valuation - The fair value of the restricted stocks will be calculated using the Black-Scholes model, with parameters including a stock price of 59.25 yuan per share and a historical volatility of 14.78% to 16.97% [29][30]. - The estimated impact of the stock incentive plan on the company's financial performance will be reflected in the accounting costs, which will be amortized over the vesting period [31][32].